3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
5
Breast
2
Head & Neck
1
Gastrointestinal
1
CNS
1
Conditions
Breast Neoplasms
40
Neoplasms
4
Triple Negative Breast Neoplasms
3
Obesity
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Insulin Resistance
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Breast Cancer Female
2
Brain Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sleep Wake Disorders
1
Sezary Syndrome
1
Rectal Neoplasms
1
Racism
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Interventions
pembrolizumab
42
Paclitaxel
26
Cyclophosphamide
25
Carboplatin
23
olaparib
21
Nivolumab
16
fludarabine
15
Docetaxel
13
aldesleukin
12
Gemcitabine
11
Fulvestrant
11
veliparib
9
Bevacizumab
9
sargramostim
8
palbociclib
8
durvalumab
8
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
liposomal doxorubicin
7
atezolizumab
7
Surveys and Questionnaires
7
Ipilimumab
7
Blood Specimen Collection
7
niraparib
6
avelumab
6
Taxes
6
Specimen Handling
6
Interleukin-2
6
Fluorouracil
6
Cisplatin
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Metformin
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn